Back to Search Start Over

Uniting biobank resources reveals novel genetic pathways modulating susceptibility for atopic dermatitis

Authors :
FinnGen
Estonian Biobank Research Team
Sliz, Eeva
Huilaja, Laura
Pasanen, Anu
Laisk, Triin
Reimann, Ene
Mägi, Reedik
Hannula-Jouppi, Katariina
Peltonen, Sirkku
Salmi, Teea
Koulu, Leena
Tasanen, Kaisa
Kettunen, Johannes
Tampere University
Department of Respiratory medicine, Dermatology and Allergology
Clinical Medicine
Department of Dermatology, Allergology and Venereology
HUS Inflammation Center
Clinicum
Research Programs Unit
University of Helsinki
STEMM - Stem Cells and Metabolism Research Program
Source :
Journal of Allergy and Clinical Immunology. 149:1105-1112.e9
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

Publisher Copyright: © 2021 The Authors Background: Atopic dermatitis (AD) is a common chronic inflammatory skin disease with high heritability. Previous genome-wide association studies have identified several loci predisposing to AD. These findings explain approximately 30% of the variance in AD susceptibility, suggesting that further work is required to fully understand the genetic underpinnings. Objective: We sought to gain additional understanding of the genetic contribution to AD risk by using biobank resources. Methods: We completed a genome-wide meta-analysis of AD in 796,661 individuals (Ncases = 22,474) from the FinnGen study, the Estonian Biobank, and the UK Biobank. We further performed downstream in silico analyses to characterize the risk variants at the novel loci. Results: We report 30 loci associating with AD (P < 5 × 10−8), 5 of which are novel. In 2 of the novel loci, we identified missense mutations with deleterious predictions in desmocollin 1 and serpin family B member 7, genes encoding proteins crucial to epidermal strength and integrity. Conclusions: These findings elucidate novel genetic pathways involved in AD pathophysiology. The likely involvement of desmocollin 1 and serpin family B member 7 in AD pathogenesis may offer opportunities for the development of novel treatment strategies for AD in the future.

Details

ISSN :
00916749
Volume :
149
Database :
OpenAIRE
Journal :
Journal of Allergy and Clinical Immunology
Accession number :
edsair.doi.dedup.....9c85760a1350ea195a21d7bff012d37a
Full Text :
https://doi.org/10.1016/j.jaci.2021.07.043